Immunome, inc.IMNM.US Overview

US StockHealthcare

(No presentation for IMNM)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

IMNM Overall Performance

IMNM AI Analysis & Strategy

IMNM Recent Performance

0.27%

Immunome, inc.

0.81%

Avg of Sector

-1.14%

S&P500

IMNM PowerScanner

IMNM Key Information

IMNM Valuation Metrics

IMNM Earnings Table

IMNM Profile

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.